Results 271 to 280 of about 126,758 (293)

Phase IIa study of the CD19 antibody MOR208 in patients with relapsed or refractory B-cell non-Hodgkin’s lymphoma

Annals of Oncology, 2018
W Jurczak, Pier Luigi Zinzani, Gianluca Gaidano   +2 more
exaly  

Optimized CD19/CD22/CD3 antibody

Blood, 2022
openaire   +2 more sources

Phase 1 Results of ZUMA-1: A Multicenter Study of KTE-C19 Anti-CD19 CAR T Cell Therapy in Refractory Aggressive Lymphoma

Molecular Therapy, 2017
Frederick L Locke, Sattva S Neelapu, Nancy L Bartlett   +2 more
exaly  

Beyond CD19

Advances in Oncology
Erin E. Doherty, Helen E. Heslop
openaire   +1 more source

CD19 regulates B lymphocyte responses to transmembrane signals

Seminars in Immunology, 1998
Manabu Fujimoto, Jonathan C Poe, Thomas F Tedder   +2 more
exaly  

CD19+ tumor-infiltrating B-cells prime CD4+ T-cell immunity and predict platinum-based chemotherapy efficacy in muscle-invasive bladder cancer

Cancer Immunology, Immunotherapy, 2018
Qi Jiang, Qiang Fu, Junyu Zhang
exaly  

Allogeneic CD19-targeted CAR-T therapy in patients with severe myositis and systemic sclerosis

Cell
Xinyi Wan, Jialin Song, Lingying Ye
exaly  

CD19 Deficiency

2012
openaire   +1 more source

An iPSC-derived CD19/BCMA CAR-NK therapy in a patient with systemic sclerosis

Cell
Yanan Yue, Kun Pang
exaly  

CD19 Molecule

2018
openaire   +1 more source